Market Research Logo

Global Colorectal Cancer Market: Industry Analysis & Outlook (2021-2025)

Global Colorectal Cancer Market: Industry Analysis & Outlook (2021-2025)

Colorectal cancer (CRC), also known as bowel cancer and colon cancer, is the development of cancer from the colon or rectum (parts of the large intestine). A cancer is the abnormal growth of cells that has the ability to invade or spread to other parts of the body. Signs and symptoms for this cancer may include blood in the stool, a change in bowel movements, weight loss, and feeling tired all the time. The current screening regime for this disease comprises of gFOBT, FIT, flexible Sigmoidoscopy, Colonoscopy and others. Further, the treatment for CRC is limited to surgery, chemotherapy and radiotherapy or adjuvant therapies.

The global CRC market would be driven by factors such as rising geriatric population, better reimbursement policies, growing number of obese people and others. However, the dynamics such as stringent regulatory norms, side effects of therapies and high cost of screening tests or drugs are expected to act as a threat for market’s growth. Rising awareness regarding the incidence of CRC and importance of diagnosis has propelled higher compliance with regular tests. Further, in order to harness the market potential, various companies are involved in developing lesser invasive and easy to use screening methods.

The report “Global Colorectal Cancer Market: Industry Analysis & Outlook (2021-2025)” provides a comprehensive study of global market and also major regional markets. Furthermore, market dynamics such as key trends and development; and challenges are analyzed in-depth. The global market is highly competitive consisting of several large enterprises including Bayer AG, Roche Holding AG, Merck & Co., Inc. and Eli Lilly and Company. The competitive landscape of the respective market, along with the company profiles of leading players are discussed in detail.


1. Overview
1.1 Colorectal Cancer
1.2 Signs, Symptoms and Stages
Table 1: Stages of Colorectal Cancer
1.3 Diagnosis
1.4 Treatment
Table 2: Treatment Option for Colorectal Cancer
2. Global Colorectal Cancer Market
2.1 Global Cancer Diagnostics Market Forecast by Value
Table 3: Global Cancer Diagnostics Market Forecast by Value (2021-2025)
2.2 Global CRC Screening Patient Volume Forecast
Table 4: Global CRC Screening Patient Volume Forecast (2021-2025)
2.3 Global CRC Screening Patient Volume by Region
Table 5: Global CRC Screening Patient Volume by Region (2021)
2.4 Global CRC Screening Product Market
2.4.1 Global C-Scan Cap Revenue Forecast
Table 6: Global C-Scan Cap Revenue Forecast (2021-2025)
2.5 Global CRC Patients on Drugs by Volume
Table 7: Global CRC Patients on Drugs by Volume (2021-2025)
2.6 Global CRC Patients on Drugs by Region
Table 8: Global CRC Patients on Drugs by Region (2021)
2.7 Global CRC Patients on Drugs by Segments
Table 9: Global CRC Patients on Drugs by Segments (2021)
2.8 Global CRC Drug Market
2.8.1 Global Modufolin Revenue Forecast
Table 10: Global Modufolin Revenue Forecast by Value (2021-2025)
2.8.2 Global Modufolin Revenue Forecast by Segments
Table 11: Global Modufolin Revenue Forecast by Segments (2021/2025)
2.8.3 Global Modufolin Revenue as First Line Drug
Table 12: Global Modufolin Revenue as First Line Drug (2021-2025)
2.8.4 Global Modufolin Revenue as Second Line Drug
Table 13: Global Modufolin Revenue as Second Line Drug (2021-2025)
2.8.5 Global Modufolin Revenue as Third Line Drug
Table 14: Global Modufolin Revenue as Third Line Drug (2023-2025)
3. Regional Market
3.1 The US
3.1.1 The US CRC Screening Patient Volume Forecast
Table 15: The US CRC Screening Patient Volume Forecast (2021-2025)
3.1.2 The US CRC Screening Volume by Test Mix
Table 16: The US CRC Screening Volume by Test Mix (2016)
3.1.3 The US C-Scan Cap Revenue Forecast
Table 17: The US C-Scan Cap Revenue Forecast (2021-2025)
3.1.4 The US Patients on First Line CRC Drug by Volume
Table 18: The US Patients on First Line CRC Drug by Volume (2021-2025)
3.1.5 The US Patients on Second Line CRC Drug by Volume
Table 19: The US Patients on Second Line CRC Drug by Volume (2021-2025)
3.1.6 The US Patients on Third Line CRC Drug by Volume
Table 20: The US Patients on Third Line CRC Drug by Volume (2021-2025)
3.2 Europe
3.2.1 Europe CRC Screening Patient Volume Forecast
Table 21: Europe CRC Screening Patient Volume Forecast (2021-2025)
3.2.2 Europe C-Scan Cap Revenue Forecast
Table 22: Europe C-Scan Cap Revenue Forecast (2021-2025)
3.2.3 Europe Patients on First Line CRC Drug by Volume
Table 23: Europe Patients on First Line CRC Drug by Volume (2021-2025)
3.2.4 Europe Patients on Second Line CRC Drug by Volume
Table 24: Europe Patients on Second Line CRC Drug by Volume (2021-2025)
3.2.5 Europe Patients on Third Line CRC Drug by Volume
Table 25: Europe Patients on Third Line CRC Drug by Volume (2021-2025)
4. Market Dynamics
4.1 Growth Drivers
4.1.1 Growing Geriatric Population
Table 26: Global Geriatric Population (2012-2016)
4.1.2 Rising Healthcare Expenditure
Table 27: Global Healthcare Expenditure Per Capita (2012-2016)
4.1.3 Growing Global GDP per Capita
Table 28: Global GDP Per Capita (2012-2016)
4.1.4 Surging Obese Population
Table 29: Global Obese Population (2012-2016)
4.1.5 Rising Awareness Regarding CRC
4.2 Key Trends & Development
4.2.1 Rising Compliance to CRC Screening
Table 30: Percentage of Adults in Compliance in the US (2012-2016)
4.2.2 Development of New CRC Drugs
Table 31: Number of New CRC Drugs Under Pipeline (2016)
4.3 Challenges
4.3.1 High Cost of Screening and Drugs
4.3.2 Side Effects of Drugs
4.3.3 Stringent Drug Approval Process
Table 32: Drug Approval Process
5. Competitive Landscape
5.1 Global CRC Market
5.1.1 Revenue and Market Cap. Comparison
Table 33: Revenue and Market Cap. Comparison (2016)
5.2 Global CRC Drugs Market
5.1.2 Global CRC Drugs Market by Company Share
Table 34: Global CRC Drugs Market by Company Share (2016)
5.3 Global CRC Screening Market
5.3.1 DNA based CRC Screening Tests Comparison
Table 35: DNA based CRC Screening Tests Comparison (2016)
6. Company Profiles
6.1 Bayer AG
6.1.1 Business Overview
Table 36: Bayer AG Net Sales by Segment (2016)
6.1.2 Financial Overview
Table 37: Bayer AG Net Sales and Net Income (2012-2016)
6.1.3 Business Strategies
Table 38: Bayer AG R&D Expenditure (2014-2016)
6.2 Roche Holding AG
6.2.1 Business Overview
Table 39: Roche Holding AG Sales by Segment (2016)
6.2.2 Financial Overview
Table 40: Roche Holding AG Sales and Net Income (2012-2016)
6.2.3 Business Strategies
Table 41: Roche Holding AG R&D Expenditure (2014-2016)
Table 42: Number of Products In Pipeline by Segments (2016)
6.3 Merck & Co., Inc.
6.3.1 Business Overview
Table 43: Merck & Co., Inc. Sales by Segment (2016)
6.3.2 Financial Overview
Table 44: Merck & Co., Inc.’s Sales and Net Income (2012-2016)
6.3.3 Business Strategies
Table 45: Merck & Co., Inc.’s R&D Expenditure (2014-2016)
6.4 Eli Lilly and Company
6.4.1 Business Overview
Table 46: Eli Lilly and Company Revenue by Segment (2016)
6.4.2 Financial Overview
Table 47: Eli Lilly and Company Revenue and Net Income (2012-2016)
6.4.3 Business Strategies
Table 48: Eli Lilly and Company R&D Expenditure (2014-2016)

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report